Aug. 26 at 5:59 PM
$GALT That seeking alpha article was poorly researched and superficial at best. Author has little understanding of the clinical staging of MASH and cirrhosis and seems to ignore the fact the company is majority owned and funded by one of America’s most successful private business owners. Comparing
$MDGL or
$AKRO Efruxifermin (EFX)
FGF21 analog targeting FGFR/β-Klotho and Madrigal Rezdiffra (resmetirom)THR-β agonist (thyroid hormone receptor) to a true anti-fibrotic mechanism in a cirrhosis population shows the lack nuanced understanding of the disease states and mechanisms at play here. Edmund this was a poor amateur analysis at best.
https://seekingalpha.com/symbol/GALT
https://talkmarkets.com/content/stocks--equities/galectin-therapeutics-is-undervalued-and-with-short-squeeze-underway?post=504960
